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This review aims to verify the main epidemiologic, clinical, laboratory-related, and therapeutic aspects of
coronavirus disease 2019 (COVID-19) in critically ill pediatric patients.
An extensive review of the medical literature on COVID-19 was performed, mainly focusing on the critical care
of pediatric patients, considering expert opinions and recent reports related to this new disease. Experts from
a large Brazilian public university analyzed all recently published material to produce a report aiming to
standardize the care of critically ill children and adolescents.
The report emphasizes on the clinical presentations of the disease and ventilatory support in pediatric
patients with COVID-19. It establishes a flowchart to guide health practitioners on triaging critical cases.
COVID-19 is essentially an unknown clinical condition for the majority of pediatric intensive care profes-
sionals. Guidelines developed by experts can help all practitioners standardize their attitudes and improve the
treatment of COVID-19.
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’ INTRODUCTION
Coronavirus disease 2019 (COVID-19) is a viral respiratory
illness caused by severe acute respiratory syndrome corona-
virus 2 (SARS-CoV-2), a single-stranded RNAvirus that most
likely originated in bats. The virus is thought to spread
mainly from person-to-person via close contact (the virus can
be transferred from the hands to the eyes, nose, or mouth)
and respiratory droplets (produced when an infected person
coughs or sneezes). There is no evidence of vertical trans-
mission or transmission via breastfeeding. Transmission from
asymptomatic or mildly symptomatic carriers or during the
incubation period, estimated to be between 1 and 14 days
(mean, 5 days), can also occur; 95% of patients develop
symptoms up to 12.5 days after exposure. This gave rise to the
established quarantine period of 14 days after exposure (1,2).
Clinical presentation
The clinical spectrum of COVID-19 ranges from being
asymptomatic to being in severe acute respiratory distress
(Figure 1) (3).
According to a case series of 2143 pediatric patients (3)
registered in the China Center for Disease Control and
Prevention (CDC) database, 731 cases were confirmed using
laboratory testing, 94 (4.4%) patients were asymptomatic,
1091 (50.9%) patients presented with mild symptoms, and
831 (38.8%) patients presented with moderate symptoms.
Only 125 (5.8%) patients developed severe or critical disease.
Younger children were more susceptible to severe or cri-
tical symptoms (10.6% o1 year old vs. 3% X16 years old);
there were 13 critical cases, and in seven (53.8%) of them
the patient was less than 1 year old. Only one death was
reported, that is, of a 14-year-old boy.
According to another series of 171 pediatric cases (4)
(1 day to 15 years old; median, 6.7 years) admitted to a hospital
in Wuhan, China, all patients tested positive for COVID-19,
27 (15.8%) were asymptomatic, 33 (19.3%) had upper airway
symptoms, and 111 (64.9%) had pneumonia. Seventy-one
pediatric patients presented with fever (41.5%) which lasted
1 to 16 days (median, 3 days). Three patients were admitted
to the intensive care unit; all of them had comorbidities such
as hydronephrosis, leukemia (during chemotherapy), and
intussusception. The patient presenting with intussusception
was 10 months old; the patient’s condition deteriorated,
leading to multiple organ dysfunction and death.
Various cutaneous rashes have been recently observed in
some pediatric cases with variable clinical presentations (5,6).
Laboratory findings
The white blood cell count can be normal or reduced.
A series of 171 pediatric cases of COVID-19 reported leukopenia
in 26.3% of patients; only 3.5% developed lymphocytopenia.
C-reactive protein levels can be normal or elevated. Severe orDOI: 10.6061/clinics/2020/e1894
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critical cases may be accompanied by an elevation in hepatic
and muscular enzyme levels and high D-dimer levels (2,4).
Imaging findings
During the initial phase of illness, chest radiography
findings can show signs of pneumonia, such as small
irregular lung opacities and interstitial alterations, usually
affecting peripheral areas. Ground glass opacities (GGO) and
consolidation may be observed in severe cases. Pleural
effusion is uncommon. Chest computed tomography also
exhibits GGO and segmental consolidation in both lungs.
Children presenting with severe infection may show lobar
consolidation bilaterally (2). Lung ultrasonography (US)
exhibits single or grouped, usually bilateral, pneumogenic-
type vertical artifacts and/or small areas of white lung.
Advanced COVID-19 pneumonia is characterized by evident
consolidation, particularly in the posterobasal regions, and
widespread patched artifactual changes, similar to those in
acute respiratory distress syndrome (ARDS) (7). Thoracic
electrical impedance tomography can be used to monitor the
distribution of regional ventilation in patients with ARDS
and to identify refractory hypoxemia that requires alveolar
recruitment maneuvers.
Detection of etiological agent
The detection of SARS-CoV-2 nucleic acid using real-time
reverse transcriptase-polymerase chain reaction (RT-PCR) is
the reference standard for COVID-19 diagnosis. The virus
can be detected in upper airway or inferior airway secretions
(nasopharynx swab or tracheal aspirates [if intubated],
sputum, and bronchoalveolar lavage), blood, urine, and
stool (1,8).
In a case series of 10 pediatric patients from Shanghai (9),
viral RNA was detected in the nasopharynx of all patients
from 4 to 48h after the beginning of symptoms up to 6 to
22 days (mean, 12 days) after the first day of illness. In five
patients, SARS-CoV-2 RNA was detected in the stool until
18 to 30 days after the initial symptoms.
According to the 22-38 SS Resolution, 3-17-2020, from São
Paulo’s State Health Secretary (10), RT-PCR for SARS-CoV-2
should be performed only for patients in a severe or critical
condition, those in sentinel units, and health care profes-
sionals with symptoms typical of COVID-19. The test should
not be performed in asymptomatic individuals.
Diagnostic criteria
A diagnosis is made considering clinical findings, epide-
miology, and laboratory testing to confirm SARS-CoV-2
infection (2). Figure 2 shows the flowchart for patients with
flu-like symptoms as proposed by the São Paulo State Health
Secretary (10,11).
Differential diagnosis
Other viral respiratory illnesses. Respiratory syncytial
virus, influenza, parainfluenza, adenovirus, and metapneu-
movirus are frequent causes of lower airway infection in
children and have similar clinical presentation to COVID-19.
The diagnosis can be made by identifying the etiological agent
in respiratory secretions using polymerase chain reaction.
Bacterial pneumonia. The main clinical manifestations
of bacterial pneumonia are high fever and toxemic state.





Frequently, there is leukocytosis with neutrophilia and
increased numbers of younger cells. Blood and aspirate
tracheal cultures are very important. Bronchoalveolar lavage
(BAL) in intubated patients can be very useful in making a
diagnosis.
Atypical pneumonia. Mycoplasma pneumoniae and Chla-
mydia pneumoniae are important causative agents of commu-
nity-acquired pneumonia in children, and serologic tests can
be used to confirm the diagnosis (2).
Therapeutic management
The four main principles for adequate therapeutic manage-
ment are early identification, early isolation, early diagnosis,
and early treatment. When dealing with a case of suspected
COVID-19, the patient should be kept in a single room with
all precautions to prevent and control infections before
laboratorial confirmation. Mild cases should be treated
with symptomatic relief medication, preferably paracetamol
or dipyrone, to control fever. Antiviral agents, including
oseltamivir, ribavirin, ganciclovir, remdesivir, lopinavir, and
ritonavir, have been used to reduce the viral load to prevent
potential respiratory complications but with no apparent
benefits thus far (1,2,12). A Chinese study (13) of more than
100 patients reported that chloroquine was secure and
effective in treating COVID-19-associated pneumonia, inhi-
biting exacerbation of pneumonia, reducing radiographic
alterations, promoting virus elimination, and decreasing the
Figure 2 - Flu-like syndrome flowchart.
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period of time of the disease. Another French study (14)
enrolled 20 patients with COVID-19 and showed that
treatment with hydroxychloroquine was associated with
cure of the viral infection, with the utilization of azithro-
mycin leading to increased benefit. There are other current
studies analyzing the drug’s efficiency in critically ill patients
with a higher risk of death and considering the use of
hydroxychloroquine/chloroquine (5–10 mg/kg/day of basic
chloroquine for 10 days) and azithromycin (10 mg/kg on
the first day, followed by 5 mg/kg/day for 4 days with
a maximum dose of 30 mg/kg or 1,500 mg) (14-16).
Severe cases with respiratory distress and/or hypoxia (SaO2
o94%) (Severe Acute Respiratory Syndrome) should be
admitted to the hospital. Indications for ICU admission are:
respiratory failure requiring mechanical ventilation, shock or
other organ dysfunction requiring treatment (9,17). The main
characteristic of the critical cases is the occurrence of ARDS
with hypoxemic acute respiratory distress and bilateral
pulmonary infiltrates that are not explained by cardiac
dysfunction or fluid overload. The main treatment princi-
ples of ARDS are as follows (17-20):
 Early tracheal intubation – rapid sequence intubation is the
best practice in this situation. Preoxygenation should be per-
formed using a flexible nasal cannula (up to flows of 4 L/min)
or a reservoir mask with a lower flux to maintain an SaO2
493%. Positive pressure ventilation with a bag-valve-mask
or other similar apparatus should be avoided to not generate
aerosols. Sedation can be performed using fentanyl (1–2 mg/
kg) or ketamine (1–2 mg/kg, if there is no contraindication
such as pulmonary hypertension) and neuromuscular block-
ing with rocuronium (0.6–1.2 mg/kg), preferably. Video
laryngoscopy should be utilized if available.
 Non-invasive ventilation (NIV) should be avoided because
of the high risk of aerosol dispersion and contamination
among health practitioners.
 Protective mechanical ventilation using a pressure con-
trolled or volume cycled, with a low tidal volume (around
6 mL/kg) and plateau pressure p30 cmH2O. The positive
end-expiratory pressure (PEEP) should be titrated such
that FiO2 is reduced (p50%), with PaO2 460 mmHg and
SaO2 490–93%. The general recommendation is to start
with PEEP at 5–6 cmH2O and increase progressively to
12–14 cmH2O if necessary. It is very important to maintain
a driving pressure (plateau pressure – PEEP) o15 cmH2O
and tolerate hypercapnia with pH 47.2 (permissive hyper-
capnia), except for patients with pulmonary hypertension.
 Prone positioning, especially if PaO2/FiO2 o150 mmHg.
The patient should be maintained in this position at least
18 hours per day with oximetry and capnography monitoring.
 Closed tracheal aspiration systems should be used.
 Treatment with nitric oxide and/or sildenafil (0.5–2 mg/
kg/dose each 4–6 hours with a maximum of 20 mg/dose
each 8 hours) for patients with persistent hypoxemia. Veno-
venous extracorporeal membrane oxygenation (ECMO) can
be used in patients with PaO2/FiO2 o70–80 mmHg in
whom conventional treatment (protective mechanical ven-
tilation, prone positioning, nitric oxide/sildenafil) was not
successful, according to its availability in the hospital.
 Conservative fluid therapy, including volume restriction in
patients with hemodynamic stability, starting with 50% of
the normal recommendation based on the Holliday-Segar
rule, and adjustments according to the fluid balance and
hemodynamic clinical conditions.
Patients with wheezing and lower airway obstruction
should be treated with the aim of reducing respiratory
droplet dispersion inside the environment. Aerosol bronch-
odilators should be avoided and spray or dosimetric inhalers
should be used. It is possible to utilize NIV in some cases but
it should use a mechanical ventilator with a double circuit,
with filters in both parts (to warm and humidify in the
inspiratory circuit and a high-efficiency particle separator in
the expiratory circuit). It is necessary to emphasize that NIV
support has been used in isolation hospital rooms with
negative pressure only. After 1 to 2 hours of non-invasive
mechanical ventilation without adequate evolution, tracheal
intubation is recommended. Mechanical ventilation support
should avoid pulmonary hyperinsufflation, auto-PEEP, and
barotrauma. Pressure-controlled ventilation is preferred in
synchronized intermittent mandatory ventilation with sup-
port pressure, low breathing rate, inspiration/expiration
time rate of 1:3–1:4 and PEEP=5 cmH2O.
Antibiotics should be used only in patients with secondary
bacterial infections on the basis of the culture and antibiogram
results. Corticosteroids can suppress lung inflammation but
also inhibit immune responses and pathogen clearance, and
should be avoided except for those with a specific indication
(e.g., bronchospasm or some cases of septic shock) (1,2). There
is a report that intravenous immunoglobulin treatment in a
3-year-old critically ill child was effective (21). Patients with
cardiocirculatory dysfunction and shock should be treated
with fluid therapy or vasoactive/inotropic drugs. Milrinone
(0.1–1.0 mg/kg/min) or dobutamine (5–15 mg/kg/min) can be
useful in patients with a low cardiac index as a consequence of
pulmonary hypertension and normal arterial pressure. Epi-
nephrine at an inotropic dose (p0.3 mg/kg/min) can be used
in patients with hypotension. In children and adolescents with
other organic dysfunctions, continuous renal replacement
therapy may be necessary because renal dysfunction is an
indicator of a poor prognosis (1,2,7). Microthrombosis and
associated ischemic events are very common (e.g., strokes),
mainly in adolescents and adults. D-dimer levels should be
monitored frequently.
Appropriate medical transport for the patient (and their
parent/caregiver) to the hospital should be provided by
medical transport teams. Community pediatricians should
advise parents to wait for this service and to not seek secon-
dary care themselves, for example, by going to the hospital
via car or public transport (22).
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